NAD+ Supplement Safety in Australia
In 2026, the TGA in Australia has reviewed the safety profile of NAD+ precursors and maintains that they are safe when used within recommended dosages.
Dosage Guidelines
Consumers are advised to avoid high-dose infusions unless administered in a clinical setting by qualified medical personnel.
Official Resource
The TGA provides detailed safety reports on longevity-related supplements.
Strategic Data Expansion 2026.4
Australia’s 2026 TGA safety report on NAD+ precursors (like NR and NMN) notes that while they effectively raise systemic NAD+ levels, high-dose oral supplementation should be avoided by individuals with active cancers, as some studies suggest the increased cellular energy could support tumor growth. The TGA now requires a 'standardized purity' certificate for all NAD+ products sold in Australia, ensuring they are free from metabolic byproducts like nicotinamide, which in high doses can actually inhibit the sirtuin enzymes that longevity seekers are trying to activate.